欢迎访问《现代生物医学进展》编辑部！

小细胞肺癌（small cell lung cancer，SCLC）约占肺癌患者总数的15%-20%，与吸烟关系密切，约60%-70%的患者就诊时已处于广泛期，预后很差，内科药物治疗仍然为其主要的治疗手段。由于其细胞生物学行为复杂，恶性程度高，易出现复发及耐药，通过多药联合、优化给药顺序、改变用药方法及调整药物剂量强度并没有获得预期的疗效，且毒副反应较多，其死亡率依然高居各种肿瘤之首，寻求有效的治疗方案变得迫切而棘手。近年来，随着SCLC 内科治疗药物研究的不断深入，一些研究热点药物如 bcl-2 抑制剂、Hedgehog信号通路抑制剂、ipilimumab、贝伐单抗等已在Ⅱ期或Ⅲ期试验中显示出良好的抗肿瘤活性，为SCLC 的药物治疗提供了新的方向。本文就目前针对SCLC 的药物治疗进展情况作一综述。

英文摘要:

Small cell lung cancer (SCLC) accounts for about 15%-20%of lung cancers, and smoking is closely related. About 60%-70% of the patients are in extensive stage when attended, and medical therapy remains their primary means of treatment but with poor prognosis. Because of its complex biological behavior, malignance, relapse and drug resistance, a multi-drug combination, changing the order and methods of chemotherapeutic agents and adjustment of dose intensity did not get any therapeutic effect. With the toxicity and highly malignance, its mortality rate is the highest in varieties of tumors. Therefore, searching for effective treatment ways is urgent but difficult. In recent years, with the constant development of pharmaceutical research on SCLC, some hot drugs, such as bcl-2 inhibitors, Hedgehog signaling pathway inhibitor, ipilimumab and bevacizumab, have shown good anti-tumor activity in phase Ⅱ and phase Ⅲ clinical trials, providing novel ways for research on anticancer drugs of SCLC. Here, we review current progress in drug therapy for SCLC.

View Full Text View/Add Comment Download reader